---
document_datetime: 2025-12-02 04:51:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tamiflu.html
document_name: tamiflu.html
version: success
processing_time: 0.4337316
conversion_datetime: 2025-12-28 01:53:09.532447
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tamiflu

[RSS](/en/individual-human-medicine.xml/66564)

##### Authorised

This medicine is authorised for use in the European Union

oseltamivir Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tamiflu](#news-on)
- [More information on Tamiflu](#more-information-on-tamiflu-1362)
- [More information on Tamiflu](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Tamiflu is an antiviral medicine used to treat or prevent influenza (flu).

- to treat flu, it can be used in adults and children (including full-term newborns) who have the symptoms of flu, when the flu virus is circulating in the community;
- to prevent flu, it can be used in adults and children over 1 year of age who have been in contact with someone who has flu and flu is circulating in the community. This is generally done on a case-by-case basis. Tamiflu can also be used as preventative treatment in exceptional cases, for instance when the seasonal flu vaccine may not provide sufficient protection and when there is a pandemic (a global epidemic of flu). During a flu pandemic, Tamiflu can also be used to prevent flu in babies below 1 year of age.

Tamiflu cannot replace flu vaccination, and its use should be based on official recommendations.

The medicine contains the active substance oseltamivir.

Expand section

Collapse section

## How is Tamiflu used?

Tamiflu is available as capsules (30 mg, 45 mg, and 75 mg) and as a powder that is made up into a liquid to be drunk (6 mg/ml and 12 mg/ml).

In the treatment of flu, Tamiflu must be started within two days of the onset of symptoms. The usual dose for adults and children weighing more than 40 kg is 75 mg given twice a day for 5 days. For adults with a weakened immune system (the body's natural defences), it is given for 10 days.

In the prevention of flu, Tamiflu must be started within two days of contact with someone who has flu. The usual dose for adults and children weighing more than 40 kg is 75 mg given once a day for at least 10 days after contact with an infected person. When Tamiflu is used during a flu epidemic, it is given for up to 6 weeks.

The medicine can only be obtained with a prescription. For more information about using Tamiflu, see the package leaflet or contact your doctor or pharmacist.

## How does Tamiflu work?

The active substance in Tamiflu, oseltamivir, acts on the flu virus, blocking some of the enzymes on its surface known as neuramidases. When the neuramidases are blocked, the virus cannot spread. Oseltamivir works on the neuramidases of both influenza A (the most common type) and influenza B viruses.

## What benefits of Tamiflu have been shown in studies?

**Treatment of flu**

Tamiflu reduced the duration of the illness compared with placebo (a dummy treatment) in several studies (involving 2,413 patients aged 13 years or over, 741 elderly patients aged 65 years or over and 1,033 children aged between 1 and 12 years). Effectiveness was measured by recording symptoms (feeling feverish, muscle pain, headache, sore throat, cough, overall discomfort and runny nose). In adults, the duration of the illness was reduced from an average of 5.2 days for patients taking placebo, to 4.2 days for patients taking Tamiflu. The average reduction in the duration of the illness in children aged 1 to 6 years was 1.5 days.

**Prevention of flu**

Tamiflu reduced the incidence of flu in people who had come into contact with the disease when one of their family members contracted flu (962 cases) or during an epidemic (1,562 people aged between 16 and 65 years, and 548 elderly people in nursing homes). The studies measured the number of cases of flu proven by laboratory tests. A study also looked at using Tamiflu in a family setting (277 families) for both the treatment of the person with flu, and the treatment or prevention of flu in those in contact with the person.

In the study carried out during an epidemic, 1% of the people taking Tamiflu developed flu after contact, compared with 5% of those taking placebo. In families with one patient who had flu, 7% of the family members in the household developed flu when receiving Tamiflu, compared with 20% of those receiving no preventative treatment.

## What are the risks associated with Tamiflu?

The most common side effects with Tamiflu (seen in more than 1 patient in 10) in adults and adolescents are headache and nausea (feeling sick). In children the most common side effects (seen in more than 1 patient in 10) are vomiting, cough and nasal congestion (a blocked nose). For the full list of side effects and restrictions with Tamiflu, see the package leaflet.

## Why is Tamiflu authorised in the EU?

When used for treatment of flu, Tamiflu reduces the duration of illness in adults and children. It can also reduce the incidence of flu in patients who had come into contact with the disease or during a pandemic. Side effects are generally mild or moderate in severity.

The European Medicines Agency decided that Tamiflu's benefits are greater than its risks and recommended that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Tamiflu?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tamiflu have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tamiflu are continuously monitored. Side effects reported with Tamiflu are carefully evaluated and any necessary action taken to protect patients.

## Other information about Tamiflu

Tamiflu received a marketing authorisation valid throughout the EU on 20 June 2002.

Tamiflu : EPAR - Medicine overview

Reference Number: EMA/506592/2012

English (EN) (83.1 KB - PDF)

**First published:** 01/12/2009

**Last updated:** 07/02/2019

[View](/en/documents/overview/tamiflu-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-529)

български (BG) (110.61 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/bg/documents/overview/tamiflu-epar-medicine-overview_bg.pdf)

español (ES) (83.03 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/es/documents/overview/tamiflu-epar-medicine-overview_es.pdf)

čeština (CS) (108.08 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/cs/documents/overview/tamiflu-epar-medicine-overview_cs.pdf)

dansk (DA) (81.91 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/da/documents/overview/tamiflu-epar-medicine-overview_da.pdf)

Deutsch (DE) (83.84 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/de/documents/overview/tamiflu-epar-medicine-overview_de.pdf)

eesti keel (ET) (82.2 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/et/documents/overview/tamiflu-epar-medicine-overview_et.pdf)

ελληνικά (EL) (117.34 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/el/documents/overview/tamiflu-epar-medicine-overview_el.pdf)

français (FR) (83.45 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/fr/documents/overview/tamiflu-epar-medicine-overview_fr.pdf)

hrvatski (HR) (103.9 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/hr/documents/overview/tamiflu-epar-medicine-overview_hr.pdf)

italiano (IT) (82.84 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/it/documents/overview/tamiflu-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (106.17 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/lv/documents/overview/tamiflu-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (106.01 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/lt/documents/overview/tamiflu-epar-medicine-overview_lt.pdf)

magyar (HU) (104.88 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/hu/documents/overview/tamiflu-epar-medicine-overview_hu.pdf)

Malti (MT) (109.12 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/mt/documents/overview/tamiflu-epar-medicine-overview_mt.pdf)

Nederlands (NL) (82.28 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/nl/documents/overview/tamiflu-epar-medicine-overview_nl.pdf)

polski (PL) (107.34 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/pl/documents/overview/tamiflu-epar-medicine-overview_pl.pdf)

português (PT) (83.16 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/pt/documents/overview/tamiflu-epar-medicine-overview_pt.pdf)

română (RO) (105.94 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/ro/documents/overview/tamiflu-epar-medicine-overview_ro.pdf)

slovenčina (SK) (107.04 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/sk/documents/overview/tamiflu-epar-medicine-overview_sk.pdf)

slovenščina (SL) (100.99 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/sl/documents/overview/tamiflu-epar-medicine-overview_sl.pdf)

Suomi (FI) (82.35 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/fi/documents/overview/tamiflu-epar-medicine-overview_fi.pdf)

svenska (SV) (82.53 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

07/02/2019

[View](/sv/documents/overview/tamiflu-epar-medicine-overview_sv.pdf)

Tamiflu : EPAR - Risk-management-plan summary

English (EN) (93.12 KB - PDF)

**First published:** 07/02/2019

**Last updated:** 23/04/2020

[View](/en/documents/rmp-summary/tamiflu-epar-risk-management-plan-summary_en.pdf)

## Product information

Tamiflu : EPAR - Product Information

English (EN) (999.5 KB - PDF)

**First published:** 01/12/2009

**Last updated:** 15/04/2025

[View](/en/documents/product-information/tamiflu-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-824)

български (BG) (1.5 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/bg/documents/product-information/tamiflu-epar-product-information_bg.pdf)

español (ES) (1.08 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/es/documents/product-information/tamiflu-epar-product-information_es.pdf)

čeština (CS) (1.15 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/cs/documents/product-information/tamiflu-epar-product-information_cs.pdf)

dansk (DA) (1.14 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/da/documents/product-information/tamiflu-epar-product-information_da.pdf)

Deutsch (DE) (1.12 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/de/documents/product-information/tamiflu-epar-product-information_de.pdf)

eesti keel (ET) (1.08 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/et/documents/product-information/tamiflu-epar-product-information_et.pdf)

ελληνικά (EL) (1.33 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/el/documents/product-information/tamiflu-epar-product-information_el.pdf)

français (FR) (1.14 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/fr/documents/product-information/tamiflu-epar-product-information_fr.pdf)

hrvatski (HR) (1.22 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/hr/documents/product-information/tamiflu-epar-product-information_hr.pdf)

íslenska (IS) (996.41 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/is/documents/product-information/tamiflu-epar-product-information_is.pdf)

italiano (IT) (1.06 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/it/documents/product-information/tamiflu-epar-product-information_it.pdf)

latviešu valoda (LV) (1.21 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/lv/documents/product-information/tamiflu-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.15 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/lt/documents/product-information/tamiflu-epar-product-information_lt.pdf)

magyar (HU) (1.22 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/hu/documents/product-information/tamiflu-epar-product-information_hu.pdf)

Malti (MT) (1.24 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/mt/documents/product-information/tamiflu-epar-product-information_mt.pdf)

Nederlands (NL) (1.12 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/nl/documents/product-information/tamiflu-epar-product-information_nl.pdf)

norsk (NO) (1001.29 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/no/documents/product-information/tamiflu-epar-product-information_no.pdf)

polski (PL) (1.24 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/pl/documents/product-information/tamiflu-epar-product-information_pl.pdf)

português (PT) (1 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/pt/documents/product-information/tamiflu-epar-product-information_pt.pdf)

română (RO) (1.15 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/ro/documents/product-information/tamiflu-epar-product-information_ro.pdf)

slovenčina (SK) (1.1 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/sk/documents/product-information/tamiflu-epar-product-information_sk.pdf)

slovenščina (SL) (1.1 MB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/sl/documents/product-information/tamiflu-epar-product-information_sl.pdf)

Suomi (FI) (976.81 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/fi/documents/product-information/tamiflu-epar-product-information_fi.pdf)

svenska (SV) (954.09 KB - PDF)

**First published:**

01/12/2009

**Last updated:**

15/04/2025

[View](/sv/documents/product-information/tamiflu-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000247267 15/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tamiflu : EPAR - All Authorised presentations

English (EN) (56.81 KB - PDF)

**First published:** 18/12/2007

**Last updated:** 20/11/2019

[View](/en/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-540)

български (BG) (85.42 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/bg/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_bg.pdf)

español (ES) (11.16 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/es/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_es.pdf)

čeština (CS) (53.23 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/cs/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (47.6 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/da/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (49.33 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/de/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (57.75 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/et/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (62.72 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/el/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_el.pdf)

français (FR) (45.22 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/fr/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (68.32 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/hr/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (47.53 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/is/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_is.pdf)

italiano (IT) (46.71 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/it/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (60.71 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/lv/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (64.64 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/lt/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (35.92 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/hu/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (63.26 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/mt/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (47.24 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/nl/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (46.25 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/no/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_no.pdf)

polski (PL) (63.85 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/pl/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_pl.pdf)

português (PT) (45.54 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/pt/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_pt.pdf)

română (RO) (53.13 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/ro/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (61.65 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/sk/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (63.88 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/sl/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (9.69 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/fi/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (49.24 KB - PDF)

**First published:**

18/12/2007

**Last updated:**

20/11/2019

[View](/sv/documents/all-authorised-presentations/tamiflu-epar-all-authorised-presentations_sv.pdf)

Tamiflu : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (15.79 KB - PDF)

**First published:** 14/06/2012

**Last updated:** 14/06/2012

[View](/en/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_en.pdf)

[Other languages (23)](#file-language-dropdown-914)

български (BG) (95.39 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/bg/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_bg.pdf)

español (ES) (13.64 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/es/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_es.pdf)

čeština (CS) (95.93 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/cs/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_cs.pdf)

dansk (DA) (15.78 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/da/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_da.pdf)

Deutsch (DE) (13.77 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/de/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_de.pdf)

eesti keel (ET) (13.36 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/et/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_et.pdf)

ελληνικά (EL) (90.28 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/el/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_el.pdf)

français (FR) (14.11 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/fr/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_fr.pdf)

íslenska (IS) (13.38 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/is/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_is.pdf)

italiano (IT) (14.13 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/it/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_it.pdf)

latviešu valoda (LV) (48.01 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/lv/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_lv.pdf)

lietuvių kalba (LT) (47 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/lt/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_lt.pdf)

magyar (HU) (57.37 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/hu/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_hu.pdf)

Malti (MT) (49.47 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/mt/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_mt.pdf)

Nederlands (NL) (13.63 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/nl/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_nl.pdf)

norsk (NO) (13.47 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/no/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_no.pdf)

polski (PL) (48.56 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/pl/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_pl.pdf)

português (PT) (14.61 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/pt/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_pt.pdf)

română (RO) (46.1 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/ro/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_ro.pdf)

slovenčina (SK) (45.21 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/sk/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_sk.pdf)

slovenščina (SL) (42.62 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/sl/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_sl.pdf)

Suomi (FI) (13.74 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/fi/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_fi.pdf)

svenska (SV) (13.36 KB - PDF)

**First published:**

14/06/2012

**Last updated:**

14/06/2012

[View](/sv/documents/conditions-member-states/tamiflu-epar-conditions-imposed-member-states-safe-and-effective-use_sv.pdf)

## Product details

Name of medicine Tamiflu Active substance oseltamivir International non-proprietary name (INN) or common name oseltamivir Therapeutic area (MeSH) Influenza, Human Anatomical therapeutic chemical (ATC) code J05AH02

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

**Treatment of influenza**

Tamiflu is indicated in adults and children including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.Prevention of influenza

- Post-exposure prevention in individuals one year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community.
- The appropriate use of Tamiflu for prevention of influenza should be determined on a case-by-case basis by the circumstances and the population requiring protection. In exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains, and a pandemic situation) seasonal prevention could be considered in individuals one year of age or older.
- Tamiflu is indicated for post-exposure prevention of influenza in infants less than 1 year of age during a pandemic-influenza outbreak.

Tamiflu is not a substitute for influenza vaccination.

The use of antivirals for the treatment and prevention of influenza should be determined on the basis of official recommendations. Decisions regarding the use of oseltamivir for treatment and prophylaxis should take into consideration what is known about the characteristics of the circulating influenza viruses, available information on influenza drug susceptibility patterns for each season and the impact of the disease in different geographical areas and patient populations.

## Authorisation details

EMA product number EMEA/H/C/000402 Marketing authorisation holder

Roche Registration GmbH

Emil-Barell-Strasse 1

Opinion adopted 21/03/2002 Marketing authorisation issued 20/06/2002 Revision 43

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tamiflu : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (142.32 KB - PDF)

**First published:** 15/04/2025

[View](/en/documents/procedural-steps-after/tamiflu-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tamiflu : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (399.05 KB - PDF)

**First published:** 01/12/2009

**Last updated:** 24/03/2023

[View](/en/documents/procedural-steps-after/tamiflu-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Tamiflu-H-C-402-II-0142: EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/114965/2020

English (EN) (3.84 MB - PDF)

**First published:** 23/04/2020

[View](/en/documents/variation-report/tamiflu-h-c-402-ii-0142-epar-assessment-report-variation_en.pdf)

Tamiflu H-C-402-P46-106 : EPAR - Assessment Report

Adopted

Reference Number: EMA/451755/2019

English (EN) (561.66 KB - PDF)

**First published:** 12/08/2019

[View](/en/documents/variation-report/tamiflu-h-c-402-p46-106-epar-assessment-report_en.pdf)

Tamiflu-H-C-402-P46-105 : EPAR - Assessment Report

Adopted

Reference Number: EMA/229024/2018

English (EN) (940.53 KB - PDF)

**First published:** 25/05/2018

**Last updated:** 25/05/2018

[View](/en/documents/variation-report/tamiflu-h-c-402-p46-105-epar-assessment-report_en.pdf)

Tamiflu-H-C-402-II-0110-G: EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/186699/2015

English (EN) (3.44 MB - PDF)

**First published:** 31/07/2015

**Last updated:** 31/07/2015

[View](/en/documents/variation-report/tamiflu-h-c-402-ii-0110-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Tamiflu

Adopted

Reference Number: EMA/186701/2015

English (EN) (72.8 KB - PDF)

**First published:** 27/03/2015

**Last updated:** 27/03/2015

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tamiflu_en.pdf)

Tamiflu-H-C-402-A20-93 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/568029/2012

English (EN) (108.63 KB - PDF)

**First published:** 21/11/2012

**Last updated:** 21/11/2012

[View](/en/documents/variation-report/tamiflu-h-c-402-a20-93-epar-assessment-report-article-20_en.pdf)

Tamiflu-H-C-402-R-89 : EPAR - Assessment Report - Renewal

Adopted

Reference Number: EMA/CHMP/104274/2012

English (EN) (533.86 KB - PDF)

**First published:** 04/10/2012

**Last updated:** 04/10/2012

[View](/en/documents/variation-report/tamiflu-h-c-402-r-89-epar-assessment-report-renewal_en.pdf)

Tamiflu H-C-402-II-70 : EPAR - Assessment Report - Variation

Adopted

English (EN) (83.77 KB - PDF)

**First published:** 01/12/2009

**Last updated:** 01/12/2009

[View](/en/documents/variation-report/tamiflu-h-c-402-ii-70-epar-assessment-report-variation_en.pdf)

Tamiflu H-C-402-II-68 : EPAR - Assessment Report - Variation

English (EN) (90.85 KB - PDF)

**First published:** 21/09/2009

**Last updated:** 21/09/2009

[View](/en/documents/variation-report/tamiflu-h-c-402-ii-68-epar-assessment-report-variation_en.pdf)

Tamiflu-H-C-402-X-44 : EPAR - Scientific Discussion - Extension

Adopted

English (EN) (102.81 KB - PDF)

**First published:** 10/11/2008

**Last updated:** 10/11/2008

[View](/en/documents/scientific-discussion-variation/tamiflu-h-c-402-x-44-epar-scientific-discussion-extension_en.pdf)

Tamiflu-H-C-402-X-45 : EPAR - Scientific Discussion - Extension

Adopted

English (EN) (102.75 KB - PDF)

**First published:** 10/11/2008

**Last updated:** 10/11/2008

[View](/en/documents/scientific-discussion-variation/tamiflu-h-c-402-x-45-epar-scientific-discussion-extension_en.pdf)

CHMP post-authorisation summary of positive opinion for Tamiflu

Reference Number: EMEA/CHMP/418336/2005

English (EN) (38.97 KB - PDF)

**First published:** 14/12/2005

**Last updated:** 14/12/2005

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tamiflu_en.pdf-0)

## Initial marketing authorisation documents

Tamiflu : EPAR - Scientific Discussion

English (EN) (297.27 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/scientific-discussion/tamiflu-epar-scientific-discussion_en.pdf)

Tamiflu : EPAR - Procedural steps taken before authorisation

English (EN) (85.81 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/procedural-steps/tamiflu-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Tamiflu

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-2015) 27/03/2015

[European Medicines Agency finalises review of medicines concerned by Roche pharmacovigilance inspection](/en/news/european-medicines-agency-finalises-review-medicines-concerned-roche-pharmacovigilance-inspection) 19/11/2013

[European Medicines Agency starts infringement procedure to investigate Roche's alleged non-compliance with pharmacovigilance obligations](/en/news/european-medicines-agency-starts-infringement-procedure-investigate-roches-alleged-non-compliance-pharmacovigilance-obligations) 23/10/2012

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 July 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-july-2012) 20/07/2012

[European Medicines Agency gives first opinion on compassionate use](/en/news/european-medicines-agency-gives-first-opinion-compassionate-use) 22/01/2010

[European Medicines Agency updates on pandemic influenza](/en/news/european-medicines-agency-updates-pandemic-influenza-0) 22/01/2010

[European Medicines Agency recommendations on extension of shelf life for Tamiflu](/en/news/european-medicines-agency-recommendations-extension-shelf-life-tamiflu) 08/05/2009

[European Medicines Agency gives guidance for use of antiviral medicines in case of a novel influenza A/H1N1 pandemic](/en/news/european-medicines-agency-gives-guidance-use-antiviral-medicines-case-novel-influenza-h1n1-pandemic) 08/05/2009

[European Medicines Agency statement on safety of Tamiflu](/en/news/european-medicines-agency-statement-safety-tamiflu) 23/03/2007

[European Medicines Agency update on the safety of Tamiflu](/en/news/european-medicines-agency-update-safety-tamiflu) 17/11/2005

#### More information on Tamiflu

Questions and answers on the review of centrally authorised medicines with ingredients manufactured at Roche Carolina Inc., Florence, United States

Reference Number: EMA/476366/2012

English (EN) (81.91 KB - PDF)

**First published:** 20/07/2012

**Last updated:** 20/07/2012

[View](/en/documents/medicine-qa/questions-and-answers-review-centrally-authorised-medicines-ingredients-manufactured-roche-carolina-inc-florence-united-states_en.pdf)

Follow-up recommendations from CHMP on novel influenza (H1N1) outbreak: Tamiflu (oseltamivir); Relenza (zanamivir)

Reference Number: EMEA/CHMP/326095/2009

English (EN) (50.94 KB - PDF)

**First published:** 29/05/2009

**Last updated:** 29/05/2009

[View](/en/documents/other/follow-recommendations-chmp-novel-influenza-h1n1-outbreak-tamiflu-oseltamivir-relenza-zanamivir_en.pdf)

Opinion of the CHMP pursuant to Article-5(3) of Regulation (EC) no 726/2004, on novel influenza (H1N1) outbreak, Tamiflu (oseltamivir), Relenza (zanamivir)

Reference Number: EMEA/CHMP/278838/2009

English (EN) (33.25 KB - PDF)

**First published:** 08/05/2009

**Last updated:** 08/05/2009

[View](/en/documents/opinion-any-scientific-matter/opinion-chmp-pursuant-article-53-regulation-ec-no-726-2004-novel-influenza-h1n1-outbreak-tamiflu-oseltamivir-relenza-zanamivir_en.pdf)

CHMP assessment report on novel influenza (H1N1) outbreak, Tamiflu (oseltamivir), Relenza (zanamivir)

Reference Number: EMEA/CHMP/287662/2009

English (EN) (271.65 KB - PDF)

**First published:** 07/05/2009

**Last updated:** 07/05/2009

[View](/en/documents/opinion-any-scientific-matter/chmp-assessment-report-novel-influenza-h1n1-outbreak-tamiflu-oseltamivir-relenza-zanamivir_en.pdf)

- [Article 5(3) opinion: Novel influenza (H1N1) outbreak: Tamiflu (oseltamivir) and Relenza (zanamivir)](/en/human-regulatory-overview/post-authorisation/referral-procedures-human-medicines/article-53-opinions-any-scientific-matter-human-medicines)

#### More information on Tamiflu

- [EMEA-000365-PIP01-08-M12 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000365-pip01-08-m12)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 15/04/2025

## Share this page

[Back to top](#main-content)